The Company
We Keep

Our Clients

We don't answer to a holding company or have growth goals or profitability targets. Our team has one objective: deliver results and ensure client happiness.

Biotech

  • Agios
  • Bluebird bio
  • Celldex Therapeutics
  • Centrexion

Agios Pharmaceuticals is a biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of cancer metabolism, which represents a breakthrough understanding of how cancer cells adapt to use more nutrients than normal cells to promote their survival and growth.

bluebird bio (NASDAQ: BLUE) is developing a broadly applicable gene therapy platform for the creation of novel treatments for diseases with few or no clinical options. The company's novel approach uses stem cells harvested from the patient's bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to the patient. bluebird bio's approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and presenting a one-time transformative therapy.

Celldex Therapeutics (NASDAQ: CLDX) is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company's pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

Centrexion Therapeutics, Inc., is focused on developing and commercializing new, non-opioid and non-surgical treatments for moderate to severe chronic pain. Centrexion Therapeutics recognizes the needs of over a quarter of a billion patients living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global problem of chronic pain.

  • Editas Medicine
  • Jounce Therapeutics
  • Loxo Oncology
  • Nektar

Editas is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The company was founded by the pioneers and world leaders in genome editing bringing specific expertise in CRISPR/Cas9 and TALENs technologies. The company’s mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically-driven diseases.

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce's proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients' quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Loxo Oncology (NASDAQ: LOXO) is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential. The company’s diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. Loxo Oncology leverages the expertise of its partners in academia and industry and our management team's deep clinical-regulatory experience to deploy focused clinical development strategies in well-defined patient populations. The company’s goal is to create important new cancer therapies as efficiently as possible to substantially benefit patients.

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

  • Neon Therapeutics
  • Pliant Therapeutics
  • Proteostasis Therapeutics
  • RaNa Therapeutics

Neon Therapeutics is focused on developing therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Their programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need. The company is committed to advancing the field of cancer immunotherapy by investing in research in neoantigen biology, epitope prediction, cancer bioinformatics, personalized therapies and advanced immune profiling of cancer patients.

Headquartered in Cambridge, MA., Neon Therapeutics is private company launched in 2015 with $55 million in Series A venture capital financing from Third Rock Ventures, Clal Biotechnology Industries and Access Industries.

Pliant Therapeutics is an early-stage biotechnology company harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases. By leveraging its powerful product engine, Pliant’s mission is to prevent or even reverse fibrosis, restoring organ function. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression and fuel biomarker discovery for efficient clinical trial design. Founded by a group of seasoned experts in fibrosis biology and medicinal chemistry, Pliant Therapeutics was launched in 2016 by Third Rock Ventures and is headquartered in Redwood City, California.

Proteostasis Therapeutics, Inc. is pursuing a novel approach to therapeutic intervention based upon an understanding of the Proteostasis Network. Advances in our ability to characterize and pharmacologically control the Proteostasis Network create new opportunities for ameliorating diseases in a number of therapeutic areas.

RaNA Therapeutics is pioneering the discovery of a new class of medicines that target RNA to selectively activate protein expression within the body’s own cells. RaNA’s novel drugs work by targeting specific genes to precisely upregulate the expression of beneficial proteins. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.

  • Revolution Medicines
  • Voyager Therapeuitcs
  • Warp Drive Bio
  • Yumanity Therapeutics

REVOLUTION Medicines is redesigning evolution’s products to treat serious diseases. The company discovers and develops new drugs by reconfiguring natural substances that are inherently rich with biological function as a result of natural selection. REVOLUTION Medicines’ innovative product engine is based on the REVEAL™ platform, which uses evolution’s lessons to inform selection of chemical scaffolds, and the REVBLOCKS™ technology, a rapid, standardized and transformative synthesis process for assembling simple chemical “building blocks” into refined natural product-like structures with optimized pharmacologic and pharmaceutical properties. Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investor Third Rock Ventures.

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.

Warp Drive Bio is driving the reemergence of natural products in the era of genomics to create breakthrough treatments that make an important difference in the lives of patients. Built upon the belief that nature is the world's most powerful medicinal chemist, Warp Drive Bio is deploying a battery of state-of-the-art technologies to access powerful drugs that are now hidden within microbes. Key to the Warp Drive Bio approach is the company's proprietary "genomic search engine" and customized search queries that enable hidden natural products to be revealed on the basis of their distinctive genomic signature. Launched in 2011 through a groundbreaking strategic partnership with Sanofi and with financing from Third Rock Ventures and Greylock Partners, the company was founded by renowned scientist Dr. Gregory Verdine, along with Dr. George Church and Dr. James Wells.

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Formed in 2014 by renowned biotech industry leader, Tony Coles, M.D., and protein folding science pioneer, Susan Lindquist, Ph.D., the company is initially focused on discovering disease-modifying therapies for patients with Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Leveraging its three integrated platforms, Yumanity’s innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding.

MDx & Device

  • Acutus Medical
  • Anika Therapeutics
  • Axonics
  • Foundation Medicine

Acutus Medical is an innovative medical device company developing a minimally invasive cardiac imaging and mapping system and catheters that have the potential to change clinical practice and improve patient outcomes in irregular and complex heart rhythm disorders. Acutus Medical is a privately held company located in San Diego, CA.

Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products range from orthopedic/joint health solutions led by Orthovisc and Monovisc, treatments for osteoarthritis, to surgical aids in the anti-adhesion and ophthalmic fields. The Company also offers aesthetic dermal fillers for the correction of facial wrinkles. Anika's Italian subsidiary, Anika Therapeutics S.r.l., provides complementary HA products in the orthopedic/joint health and anti-adhesion fields, as well as therapeutics in areas such as advanced wound treatment and ear, nose, and throat care. Its regenerative technology advances Anika's vision to offer therapeutic products and medical solutions that go beyond pain relief to protect and restore damaged tissue.

Axonics, based in Irvine, CA, is a privately held venture-backed pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Foundation Medicine® (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne™ for solid tumors and FoundationOne™ Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify the molecular alterations in a patient's tumor and match them with relevant targeted therapies and clinical trials.

  • Invitae
  • IRIDEX Corporation
  • JenaValve Technology, Inc.
  • Lombard Medical

Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. They are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.

JenaValve Technology, Inc., a U.S. corporation with primary operations in Munich, Germany, develops, manufactures and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease. JenaValve was founded in 2006 by cardiologists and inventor’s Prof. Hans R. Figulla, M.D. and Prof. Markus Ferrari, M.D. The company’s transapical aortic valve system is CE marked and currently marketed in Europe and other markets worldwide. JenaValve is backed by world-class U.S., European and Asian investors.

Lombard Medical is a medical device company focused on device solutions for the $1.4 billion per annum abdominal aortic aneurysm repair market. The Company’s lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. Aorfix is the only stent graft approved for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide. Aorfix is the first AAA stent graft not of US origin to gain US FDA approval. Lombard Medical, Inc is listed on the NASDAQ Global Market under the symbol (EVAR), registered in the Cayman Islands and headquartered in Oxfordshire, England with US operations in Irvine, CA.

  • T2 Biosystems
  • 10X Genomics

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods.

10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our ChromiumTM System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.

Visionaries

  • Accelerator Corp.
  • AgTech Accelerator
  • Alexandria Real Estate Equities
  • F-Prime Capital

Accelerator is a biotechnology investment and management company with offices in New York City and Seattle. Through our consortium of top-tier investors, team of scientific thought leaders and executive managers, we identify, finance and manage the development of emerging biotechnology opportunities.

AgTech Accelerator™ is a unique startup accelerator focused on discovering and developing emerging agricultural technology companies.

Unlike other incubators that cross multiple industries or use a volume-oriented crowd-funding approach, AgTech Accelerator™ is hands-on, directly managed and leverages the same experienced management team, advisory board and board of directors across multiple opportunities, removing common business development hurdles faced by science start ups.

Alexandria Real Estate Equities, Inc. (NYSE:ARE) is an urban office REIT uniquely focused on world-class collaborative science and technology campuses in AAA innovation cluster locations. Alexandria pioneered this niche in 1994 and has since established a dominant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. Alexandria is known for its high-quality and diverse tenant base. Alexandria has a longstanding and proven track record of developing Class A assets clustered in urban science and technology campuses that provide its innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. We believe these advantages result in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

F-Prime Capital is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world’s most significant challenges in healthcare and technology. Over the past 15 years, the F-Prime Capital teams have invested in more than 89 companies in five countries across five funds. The teams have focused on innovative early-stage companies addressing significant needs in the technology and life sciences sectors.

F-Prime Capital was created in October 2015 with the joining of Fidelity Biosciences and Devonshire Investor’s technology venture capital fund.

  • The Possible Project
  • Third Rock Ventures

Founded in 2010, The Possible Project (TPP) is a youth entrepreneurship center in Cambridge, MA that teaches high school students to start and run their own businesses. It was founded by lifelong entrepreneurs Mark and Becky Levin to fulfill a dream of creating a place where young people could become entrepreneurs and in the process acquire a host of personal and professional skills that would propel them to long-term success in life, education, and their careers.

Third Rock Ventures is a venture firm focused on life sciences, investing and launching companies that make a difference in people's lives. Collaborating with entrepreneurs, the Third Rock team applies its deep expertise to establish the roadmap and building blocks for a rapidly growing and highly successful life sciences company. The Third Rock team has a unique vision and experience in building great companies, extensive academic and industry networks and a collective track record for creatively managing the value creation path to deliver exceptional performance.